This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Raad, I. I.
Right arrow Articles by Rice, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Raad, I. I.
Right arrow Articles by Rice, L. B.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2004, p. 3583-3585, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3583-3585.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.

Clinical-Use-Associated Decrease in Susceptibility of Vancomycin-Resistant Enterococcus faecium to Linezolid: a Comparison with Quinupristin-Dalfopristin

Issam I. Raad,1* Hend A. Hanna,1 Ray Y. Hachem,1 Tanya Dvorak,1 Rebecca B. Arbuckle,2 Gassan Chaiban,1 and Louis B. Rice3

Departments of Infectious Diseases, Infection Control, and Employee Health,1 Division of Pharmacy, The University of Texas M. D. Anderson Cancer Center, Houston, Texas,2 Medical Service, Louis Stokes Cleveland VA, Cleveland, Ohio3

Received 1 August 2003/ Returned for modification 25 November 2003/ Accepted 10 May 2004

The susceptibility of 135 vancomycin-resistant Enterococcus faecium bacteremic isolates to linezolid and quinupristin-dalfopristin was determined. All were susceptible to linezolid, while 88% were susceptible to quinupristin-dalfopristin prior to the clinical use of the drugs at our hospital. More than 6 months after their clinical use, a decrease in susceptibility was noted for only linezolid at 83%. This was related in part to a single G2576U gene mutation in domain V of the 23S rRNA gene.

* Corresponding author. Mailing address: The University of Texas M. D. Anderson Cancer Center, Department of Infectious Diseases, Infection Control and Employee Health (Unit 402), 1515 Holcombe Blvd., Houston, TX 77030. Phone: (713) 792-7943. Fax: (713) 792-8233. E-mail: iraad{at}mdanderson.org.

Antimicrobial Agents and Chemotherapy, September 2004, p. 3583-3585, Vol. 48, No. 9
0066-4804/04/$08.00+0     DOI: 10.1128/AAC.48.9.3583-3585.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Scheetz, M. H., Knechtel, S. A., Malczynski, M., Postelnick, M. J., Qi, C. (2008). Increasing Incidence of Linezolid-Intermediate or -Resistant, Vancomycin-Resistant Enterococcus faecium Strains Parallels Increasing Linezolid Consumption. Antimicrob. Agents Chemother. 52: 2256-2259 [Abstract] [Full Text]  
  • Seedat, J., Zick, G., Klare, I., Konstabel, C., Weiler, N., Sahly, H. (2006). Rapid Emergence of Resistance to Linezolid during Linezolid Therapy of an Enterococcus faecium Infection. Antimicrob. Agents Chemother. 50: 4217-4219 [Abstract] [Full Text]  
  • Qi, C., Zheng, X., Obias, A., Scheetz, M. H., Malczynski, M., Warren, J. R. (2006). Comparison of Testing Methods for Detection of Decreased Linezolid Susceptibility Due to G2576T Mutation of the 23S rRNA Gene in Enterococcus faecium and Enterococcus faecalis.. J. Clin. Microbiol. 44: 1098-1100 [Abstract] [Full Text]  
  • Jones, R. N., Ross, J. E., Fritsche, T. R., Sader, H. S. (2006). Oxazolidinone susceptibility patterns in 2004: report from the Zyvox(R) Annual Appraisal of Potency and Spectrum (ZAAPS) Program assessing isolates from 16 nations. J Antimicrob Chemother 57: 279-287 [Abstract] [Full Text]  
  • Hadjivassileva, T., Thurston, D. E., Taylor, P. W. (2005). Pyrrolobenzodiazepine dimers: novel sequence-selective, DNA-interactive, cross-linking agents with activity against Gram-positive bacteria. J Antimicrob Chemother 56: 513-518 [Abstract] [Full Text]  
  • Sabol, K., Patterson, J. E., Lewis, J. S. II, Owens, A., Cadena, J., Jorgensen, J. H. (2005). Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy. Antimicrob. Agents Chemother. 49: 1664-1665 [Full Text]  
  • (2004). Linezolid for Multidrug-Resistant Enterococci: A Short-Lived Success?. JWatch Infect. Diseases 2004: 1-1 [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»